Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XO-FACTOR febuxostat trial in mild hyperuricaemia and impaired glucose metabolism
2026-526401-15-00Phase 2Withdrawn
- Sponsor
- Societa Italiana Dell’ipertensione Arteriosa Lega Italiana Contro l’Ipertensione Arteriosa
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hyperuricemia, impaired glucose tolerance (IGT) and cardiometabolic disease comparing Febuxostat with Placebo (2 arms). Primary endpoint: Change in HOMA index from baseline to study end. Planned start Oct 2026; status: withdrawn.
02
Drugs
febuxostat
03
Conditions
hyperuricemiaimpaired glucose tolerance (IGT)cardiometabolic disease
Beyond the preview
Go deeper on 2026-526401-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526401-15-00.